二甲双胍联合DPP-4抑制剂对T2DM合并代谢综合征患者微炎症状态及胰岛素敏感性的影响

Effect of metformin combined with DPP-4 inhibitor on the micro-inflammatory status and insulin sensitivity of T2DM patients with metabolic syndrome

目的:探讨二甲双胍联合DPP-4抑制剂对T2DM合并代谢综合征患者微炎症状态及胰岛素敏感性的影响。方法:T2DM合并代谢综合征患者78例,回顾治疗方案并将其分为接受二甲双胍治疗的对照组41例、接受二甲双胍联合DPP-4抑制剂治疗的联合组37例,两组均持续治疗12周。对比两组微炎症状态、胰岛素敏感性的差异。结果:治疗前,两组血清中炎症因子含量、外周血中胰岛素敏感性相关指标水平的差异无统计学意义。治疗12周后,联合组患者血清中炎症因子IL-1、hs-CRP、TNF-α的含量低于对照组;胰岛素敏感指标FGP、FINS、ISI、HOMA-IR的水平低于对照组。结论:T2DM合并代谢综合征患者接受二甲双胍联合DPP-4抑制剂西格列汀治疗,可更为有效的抑制机体微炎症状态、提高胰岛素敏感性。

Objective:To investigate the effect of metformin combined with DPP-4 inhibitor on the micro-inflammatory status and insulin sensitivity of T2DM patients with metabolic syndrome.Methods:Total of 78 T2DM patients with metabolic syndrome who were treated in the hospital were retrospectively analyzed and divided into the control group(n=41)who received metformin therapy and the combined group(n=37)who received metformin combined with DPP-4 inhibitor therapy,and both groups were treated for 12 weeks.The differences in micro-inflammatory state and insulin sensitivity were compared between the two groups before and after treatment.Results:There was no statistically significant difference in serum inflammatory factor contents and peripheral blood insulin sensitivity-related index levels between the two groups before treatment.After12 weeks of treatment,serum inflammatory factors IL-1,hs-CRP and TNF-αcontents of combined group were lower than those of control group;insulin sensitivity indexes FGP,FINS,ISI and HOMA-IR levels were lower than those of control group.Conclusions:metformin combined with DPP-4 inhibitor Sitagliptin can more effectively inhibit the micro-inflammatory state and improve the insulin sensitivity in T2DM patients with metabolic syndrome.